argenx (ARGX) Aperçu de l'action
argenx SE, une société biopharmaceutique au stade commercial, développe diverses thérapies pour le traitement des maladies auto-immunes aux États-Unis, au Japon, en Chine, aux Pays-Bas et dans le monde entier. Plus de détails
| Score flocon de neige | |
|---|---|
| Évaluation | 3/6 |
| Croissance future | 5/6 |
| Performances passées | 4/6 |
| Santé financière | 5/6 |
| Dividendes | 0/6 |
ARGX Community Fair Values
Create NarrativeSee what 71 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
€686.43
FV
2.8% surévalué décote intrinsèque15.00%
Revenue growth p.a.
26
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
argenx SE Concurrents
Historique des prix et performances
| Historique des cours de bourse | |
|---|---|
| Prix actuel de l'action | €705.80 |
| Plus haut sur 52 semaines | €810.00 |
| Plus bas sur 52 semaines | €456.60 |
| Bêta | -0.057 |
| Variation sur 1 mois | 5.94% |
| Variation sur 3 mois | -0.48% |
| Variation sur 1 an | 35.57% |
| Variation sur 3 ans | 88.01% |
| Variation sur 5 ans | 212.72% |
| Évolution depuis l'introduction en bourse | 8,834.18% |
Nouvelles et mises à jour récentes
Nouveau récit • May 20
High-growth biotech compounding story if VYVGART becomes a multi-indication platform drug
Investment Memo – argenx SE 1. Executive Summary argenx is a commercial-stage biotech in immunology with an active blockbuster (VYVGART) and an advanced pipeline focused on rare autoimmune diseases.
Mise à jour du récit • May 14
ARGX: Expanded Neuromuscular Indications Will Support Future Earnings Power
Analysts nudged their blended price target for argenx higher by about €2 to roughly €845, citing a slightly higher fair value estimate, modestly adjusted growth and discount rate assumptions, and support from recent research highlighting Vyvgart momentum and an expanded late stage pipeline. Analyst Commentary Recent research shows a split between analysts trimming targets on fine tuned assumptions and others lifting or reaffirming higher fair value estimates.
Mise à jour du récit • Apr 29
ARGX: Graves And gMG Franchise Expansion Will Drive Future Repricing Potential
Analysts have nudged their argenx price targets slightly lower in recent weeks, trimming individual fair values by €30 to €92. They continue to cite ongoing Vyvgart momentum, a broader late stage pipeline and a less demanding valuation as key supports for the updated outlook.Recent updates
Nouveau récit • May 20
High-growth biotech compounding story if VYVGART becomes a multi-indication platform drug
Investment Memo – argenx SE 1. Executive Summary argenx is a commercial-stage biotech in immunology with an active blockbuster (VYVGART) and an advanced pipeline focused on rare autoimmune diseases.Mise à jour du récit • May 14
ARGX: Expanded Neuromuscular Indications Will Support Future Earnings Power
Analysts nudged their blended price target for argenx higher by about €2 to roughly €845, citing a slightly higher fair value estimate, modestly adjusted growth and discount rate assumptions, and support from recent research highlighting Vyvgart momentum and an expanded late stage pipeline. Analyst Commentary Recent research shows a split between analysts trimming targets on fine tuned assumptions and others lifting or reaffirming higher fair value estimates.Mise à jour du récit • Apr 29
ARGX: Graves And gMG Franchise Expansion Will Drive Future Repricing Potential
Analysts have nudged their argenx price targets slightly lower in recent weeks, trimming individual fair values by €30 to €92. They continue to cite ongoing Vyvgart momentum, a broader late stage pipeline and a less demanding valuation as key supports for the updated outlook.Mise à jour du récit • Apr 15
ARGX: Late Stage Neuromuscular Readouts Will Support Future Earnings Power
Analysts have made a modest upward tweak to the fair value estimate for argenx to €842.55, reflecting updated assumptions for Vyvgart momentum, slightly higher revenue growth expectations around 26.7%, a somewhat lower profit margin near 34.7%, and a higher future P/E of about 25.5x following recent price target revisions and ongoing support from research firms despite generally lower headline targets. Analyst Commentary Recent Street research on argenx reflects generally constructive views on Vyvgart execution and the broader pipeline, with some caution around spending plans and the current valuation.Mise à jour du récit • Apr 01
ARGX: Graves And gMG Expansion Will Drive Future Repricing Potential
Analysts have nudged the blended price target for argenx slightly higher to about €991. This reflects updated assumptions that pair more moderate revenue growth with a higher profit margin outlook and a somewhat richer future P/E, supported by recent research citing steady Vyvgart momentum, consistent profitability and a deep late stage pipeline.Mise à jour du récit • Mar 17
ARGX: Late Stage Neuromuscular Pipeline Readouts Will Drive Future Upside
Argenx's updated analyst price target reflects a modest recalibration, with fair value edging from about €845 to €839 as analysts factor in ongoing Vyvgart momentum, a slightly lower future P/E assumption and continued profitability. Analyst Commentary Recent Street research on argenx clusters around two themes: execution on Vyvgart and how much of that outlook is already reflected in the share price.Mise à jour du récit • Mar 03
ARGX: Expanded Neuromuscular Indications Will Drive Long Term Upside Potential
The analyst fair value estimate for argenx edges up from €825.51 to €845.07, as analysts trim long term growth and margin assumptions while still pointing to Vyvgart uptake, late stage pipeline breadth, and ongoing price targets mostly above the current level as key supports for the updated price target range. Analyst Commentary Recent Street research shows a mixed but generally constructive tone around argenx, with price targets adjusted both up and down while ratings largely stay positive.Mise à jour du récit • Feb 17
ARGX: Vyvgart Expansion Into Seronegative gMG Will Support Long Term Upside
Narrative Update Analysts have raised their average price target on argenx by a few euros to €825.51. This reflects updated models that incorporate slightly higher revenue growth assumptions, a modestly higher future P/E multiple and recent target increases from firms citing steady long term confidence in the story.
Mise à jour du récit • Feb 03
ARGX: Future Sector Correlation Risk May Undermine Elevated Biotech Thesis
Analysts have lifted their fair value estimate for argenx from US$528.05 to US$614.80, citing updated models that incorporate revised revenue growth, profit margin and future P/E assumptions, in line with a series of recent price target increases from major brokerage firms. Analyst Commentary Recent Street research on argenx has featured a series of higher price targets in both U.S. dollars and euros, reflecting updated models rather than wholesale shifts in underlying views.Mise à jour du récit • Jan 20
ARGX: Graves Disease And gMG Franchise Will Drive Future Repricing
Analysts have raised their fair value estimate for argenx from about $885 to roughly $990.88, citing higher modeled revenue growth assumptions, updated P/E expectations, and a series of price target increases across the Street. Analysts continue to view the company constructively, even as some lists are being rebalanced.Mise à jour du récit • Jan 06
ARGX: Vyvgart Franchise Expansion Will Drive Upside Despite Pipeline Setbacks
Analysts have lifted their fair value estimate for argenx from $797.32 to $820.09. This reflects updated assumptions on discount rate, revenue growth, profit margins and future P/E after recent research that highlighted solid Q3 execution, optimism around Vyvgart's opportunity and some recalibration of upside potential.Mise à jour du récit • Dec 15
ARGX: Future Pipeline Readouts Will Balance Post Rally Expectations And Execution Risks
Analysts have nudged their average price target on argenx modestly higher by about $30 per share. This reflects stronger assumed revenue growth and higher future valuation multiples, even as they temper margin expectations in light of a more selective, probability-weighted view of the Vyvgart and empasiprubart pipelines.Mise à jour du récit • Nov 30
ARGX: Share Momentum Will Balance Pipeline Progress Against Post-Rally Expectations
Argenx's analyst price target has been modestly revised downward by approximately $4 to $766. Analysts are balancing optimism on new clinical data and pipeline expansion with tempered expectations following the recent stock rally.Mise à jour du récit • Nov 16
ARGX: Shares Will Weigh Expanding Indications Against Cooling Market Enthusiasm
Analysts have raised their price target for argenx by over $20 to approximately $770. They cite strong third-quarter performance, broadening growth drivers across Vyvgart indications, and confidence in the company’s expanding pipeline and commercial prospects.Mise à jour du récit • Nov 02
ARGX: Upcoming Phase 3 Readouts and Expanded Access Will Shape Future Outlook
Argenx's analyst price target has increased by over $24 to approximately $749. Analysts cite solid quarterly results, pipeline progress, and expanded commercial opportunities as key drivers for the upward revision.Mise à jour du récit • Sep 25
Aging Trends And Genomics Will Expand Autoimmune Treatment Opportunities
argenx’s consensus price target has been revised upward to €724.38 as analysts raise growth forecasts following strong Phase 3 Vyvgart data and expanding market opportunity, while improved revenue projections and robust pipeline momentum continue to offset valuation concerns. Analyst Commentary Bullish analysts are raising price targets on Argenx following positive topline Phase 3 data for Vyvgart in seronegative myasthenia gravis and successful primary endpoint achievement across patient subtypes, which expands the addressable market.Mise à jour du récit • Aug 29
Aging Trends And Genomics Will Expand Autoimmune Treatment Opportunities
argenx’s price target has been raised to €705.90 as analysts cite strong Vyvgart Phase 3 results, raised U.S. sales expectations, visible pipeline catalysts, and resilient uptake despite recent safety concerns. Analyst Commentary Bullish analysts cite Vyvgart’s positive Phase 3 ADAPT SERON results in seronegative generalized myasthenia gravis (gMG), demonstrating clinical improvement and supporting expansion into new patient subtypes.Mise à jour du récit • Aug 06
Aging Trends And Genomics Will Expand Autoimmune Treatment Opportunities
A sharp decline in argenx’s future P/E ratio, despite slightly lower revenue growth forecasts, has contributed to a notable increase in the consensus analyst price target from €665.23 to €700.31. What's in the News Argenx and Unnatural Products Inc.Article d’analyse • Aug 01
What argenx SE's (EBR:ARGX) 25% Share Price Gain Is Not Telling You
argenx SE ( EBR:ARGX ) shares have had a really impressive month, gaining 25% after a shaky period beforehand. Looking...Article d’analyse • Jun 30
We Think argenx (EBR:ARGX) Can Stay On Top Of Its Debt
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Nouveau récit • Apr 27
Prefilled Syringe Launch And Pipeline Trials Will Expand Global Reach
Strong pipeline potential from advanced Phase III and proof-of-concept studies could drive new product approvals and market expansion, boosting revenues.Rendement pour les actionnaires
| ARGX | BE Biotechs | BE Marché | |
|---|---|---|---|
| 7D | 4.5% | 4.7% | 3.8% |
| 1Y | 35.6% | 33.3% | 22.4% |
Rendement vs Industrie: ARGX a dépassé le secteur Belgian Biotechs qui a rapporté 31.6 % au cours de l'année écoulée.
Rendement vs marché: ARGX a dépassé le marché Belgian qui a rapporté 21.4 % au cours de l'année écoulée.
Volatilité des prix
| ARGX volatility | |
|---|---|
| ARGX Average Weekly Movement | 4.5% |
| Biotechs Industry Average Movement | 8.4% |
| Market Average Movement | 4.3% |
| 10% most volatile stocks in BE Market | 7.2% |
| 10% least volatile stocks in BE Market | 2.6% |
Cours de l'action stable: ARGX n'a pas connu de volatilité de prix significative au cours des 3 derniers mois par rapport au marché Belgian.
Volatilité au fil du temps: La volatilité hebdomadaire de ARGX ( 4% ) est restée stable au cours de l'année écoulée.
À propos de l'entreprise
| Fondée | Salariés | PDG | Site web |
|---|---|---|---|
| 2008 | 1,863 | Karen Massey | argenx.com |
argenx SE, une société biopharmaceutique au stade commercial, développe diverses thérapies pour le traitement des maladies auto-immunes aux États-Unis, au Japon, en Chine, aux Pays-Bas et dans le monde entier. La société propose VYGART et VYGART HYTRULO pour traiter la myasthénie grave généralisée (MGG), la thrombocytopénie immunitaire (ITP) et la polyneuropathie inflammatoire démyélinisante chronique (CIDP). Elle développe également l'efgartigimod pour le traitement de la gMG séronégative et oculaire, des maladies oculaires thyroïdiennes, de l'ITP, de la myosite, de la maladie de Sjögren, de la néphropathie lupique, de la sclérose systémique, du rejet médié par les anticorps et de l'encéphalite auto-immune ; empasiprubart pour la neuropathie motrice multifocale, la PIDC, la fonction retardée du greffon et la dermatomyosite ; et ARGX-119 pour le syndrome myasthénique congénital, la sclérose latérale amyotrophique et l'amyotrophie spinale.
argenx SE Résumé des fondamentaux
| ARGX statistiques fondamentales | |
|---|---|
| Capitalisation boursière | €43.89b |
| Bénéfices(TTM) | €1.28b |
| Recettes(TTM) | €4.07b |
34.3x
Ratio P/E10.8x
Ratio P/SLe site ARGX est-il surévalué ?
Voir Juste valeur et analyse de l'évaluationBénéfices et recettes
| ARGX compte de résultat (TTM) | |
|---|---|
| Recettes | US$4.74b |
| Coût des recettes | US$1.99b |
| Marge brute | US$2.76b |
| Autres dépenses | US$1.27b |
| Les revenus | US$1.49b |
Derniers bénéfices déclarés
Mar 31, 2026
Prochaine date de publication des résultats
Jul 23, 2026
| Résultat par action (EPS) | 23.94 |
| Marge brute | 58.11% |
| Marge bénéficiaire nette | 31.40% |
| Ratio dettes/capitaux propres | 0.6% |
Quelles ont été les performances à long terme de ARGX?
Voir les performances historiques et les comparaisonsAnalyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/05/25 02:48 |
| Cours de l'action en fin de journée | 2026/05/25 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
argenx SE est couverte par 55 analystes. 30 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| null null | Baird |
| Colleen Kusy | Baird |
| Joel Beatty | Baird |